Biomarkers Improve Cost-Benefit Analysis of Head and Neck Cancer Immunotherapy
Biomarker May Determine Whether Perioperative Pembrolizumab Is Worth Its High Cost in Head and Neck Cancer A new economic analysis suggests that the value of pembrolizumab for patients with locally advanced head...
Read moreDetails

